Japan’s Teijin Pharma, the core company of the Teijin Group’s (TSE: 3401) health care business, has entered into a collaborative agreement with Amgen (Nasdaq: AMGN), the world’s largest independent biotech firm, to discover, develop and commercialize small molecule drugs that target RORγ.
The agreement grants Amgen an option to obtain a worldwide (ex-Japan) exclusive license to compounds discovered in the joint research collaboration, while Teijin Pharma will hold exclusive rights in Japan.
Teijin and Amgen will work together to identify candidates that modulate the activity of RORγ, an emerging and promising target for autoimmune disease drug development. RORγ is a key driver of differentiation and regulation of Th17 cells, which play a pivotal role in inflammation and are broadly implicated in autoimmune diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze